로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > TRAIL

TRAIL

요약

Name:Tumor necrosis factor ligand superfamily member 10
Target Synonym:CD253,Apo-2 ligand,TNFSF10,TNF Superfamily Member 10,APO2L,Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta,Tumor Necrosis Factor Ligand Superfamily Member 10,Tumor Necrosis Factor (Ligand) Family, Member 10,TNF-Related Apoptosis Inducing Ligand TRAIL,TNF-Related Apoptosis-Inducing Ligand,Tumor Necrosis Factor Ligand 6A,CD253 Antigen,Protein TRAIL,TNLG6A,TL2,TRAIL,Apo-2L,Tumor Necrosis Factor (Ligand) Superfamily, Member 10,Chemokine Tumor Necrosis Factor Ligand Superfamily M
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*

Synonym Name

Apo-2L,TRAIL,CD253,TNFSF10,Apo-2 ligand

Background

TRAIL, also known as  TNFSF10, APO2L, Apo-2L, CD253, TL2, TRAIL, TNLG6A and TNF superfamily member 10. The TRAIL gene as a drug target, induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
AS-1501 AS-1501 Phase 1 Clinical Shenzhen Zhongke Ai Shen Pharmaceutical Co Ltd Liver Failure; Hepatitis; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Hepatic Insufficiency Details

This web search service is supported by Google Inc.

totop